The PharmaLex- Ascent merger brings complementary expertise in clinical, regulatory and scientific affairs for clients in key markets. Credit: Arek Socha / Pixabay.

PharmaLex has entered a merger agreement with Japan-based Ascent Development Services to expand reach to Japan, East Asia and Southeast Asia.

Established in 2017, Ascent has been aiding emerging biopharma firms in understanding and tackling changes in medical practice, culture and language, which in turn helps the firms in attaining strategic and operational integration. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The merger with Ascent provides PharmaLex with access to a diverse client base and significantly expands its footprint across the globe, including in Japan and other crucial markets in East and Southeast Asia.

Through the latest merger deal, Ascent can use full-service expertise locally as well as globally for emerging biopharma companies to pursue globally integrated product development including in Asia.  

PharmaLex CEO Dr Thomas Dobmeyer said: “We are thrilled to welcome the Ascent team to the PharmaLex Group, and the opportunity to add scale and depth to our developing consulting and scientific affairs services across clinical and regulatory in markets throughout East and Southeast Asia.

“The merger enables us to continue our goal of providing integrated product development support to customers worldwide, and to serve emerging biopharma companies by integrating East and Southeast Asia into global clinical development programmes.”  

In December 2021, PharmaLex expanded its footprint in technology-facilitated smart services through a merger deal with a global life sciences organisation, pharmasol.

pharmasol offers software and hosting on a subscription basis besides pharmacovigilance (PV) services.